{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:20:13Z","timestamp":1791685213808,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kowa Company","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the intra\u2010ocular pressure (<jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>)\u2010lowering effects of a selective Rho kinase inhibitor, ripasudil (K\u2010115), over 24\u00a0hr in patients with primary open\u2010angle glaucoma (<jats:styled-content style=\"fixed-case\">POAG<\/jats:styled-content>) or ocular hypertension (<jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter, prospective, randomized, open\u2010label, 3\u2010period, Latin\u2010square crossover clinical study, 28 patients with <jats:styled-content style=\"fixed-case\">POAG<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content> whose <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> level was 21\u00a0mmHg or higher were subdivided into three groups. Each patient was treated with placebo and ripasudil in concentrations of 0.2 and 0.4%, at 9:00 and 21:00 on day 1 through a total of 3 periods separated by washout periods. <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> was measured at 9:00, 10:00, 11:00, 13:00, 16:00, 19:00, 21:00, 22:00 and 23:00 on day 1, and 1:00, 4:00, 7:00 and 9:00 on day 2 in sitting position using Goldmann applanation tonometer. Main outcome measure was the <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reduction of placebo and ripasudil from baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reduction was \u22125.2\u00a0mmHg for 0.2%, \u22126.4\u00a0mmHg for 0.4% and \u22122.0\u00a0mmHg for placebo at 2\u00a0hr after the first instillation. Also, the corresponding values were \u22126.8\u00a0mmHg for 0.2%, \u22127.3\u00a0mmHg for 0.4% and \u22124.1\u00a0mmHg for placebo at 2\u00a0hr after the second instillation. Statistically significant <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reduction, compared with placebo, was found for both 0.2 and 0.4% from 1 through 7\u00a0hr after each instillation. In safety, conjunctival hyperaemia was observed in 22 patients (79%) for 0.2%, 27 patients (96%) for 0.4% and three patients (11%) for placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ripasudil is a promising new topical medication to lower <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> for at least 7\u00a0hr after instillations in patients with <jats:styled-content style=\"fixed-case\">POAG<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.12599","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T11:39:08Z","timestamp":1418125148000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Intra\u2010ocular pressure\u2010lowering effects of a Rho kinase inhibitor, ripasudil (K\u2010115), over 24\u00a0hours in primary open\u2010angle glaucoma and ocular hypertension: a randomized, open\u2010label, crossover study"],"prefix":"10.1111","volume":"93","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Faculty of Life Sciences Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Faculty of Life Sciences Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Osaka Kosei Nenkin Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Abe","sequence":"additional","affiliation":[{"name":"The Division of Ophthalmology &amp; Visual Science Niigata University Medical &amp; Dental Hospital Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[{"name":"Kowa Company, Ltd Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Araie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Graduate School of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the K\u2010115 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,9]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00002"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32831eef4f"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1978.03910060433007"},{"key":"e_1_2_5_6_1","first-page":"74","article-title":"Acto\u2010myosin drug effects and aqueous outflow function","volume":"40","author":"Epstein DL","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.01.006"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.2573"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0666-6"},{"key":"e_1_2_5_11_1","first-page":"137","article-title":"Effects of rho\u2010associated protein kinase inhibitor Y\u201027632 on intraocular pressure and outflow facility","volume":"42","author":"Honjo M","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.8.1171"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2002.2009"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0878"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2013.874444"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8018"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.20"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.07.006"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150184006"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160145002"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0197"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080160073033"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0666"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0349"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.022"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.09.054"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00181771"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a021401"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.10.1482"},{"key":"e_1_2_5_31_1","first-page":"2566","article-title":"Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension","volume":"41","author":"Orzalesi N","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_32_1","first-page":"1029","article-title":"Modulation of aqueous humor outflow facility by the Rho kinase\u2010specific inhibitor Y\u201027632","volume":"42","author":"Rao PV","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.08.029"},{"key":"e_1_2_5_34_1","first-page":"776","article-title":"Aqueous humor flow during sleep","volume":"25","author":"Reiss GR","year":"1984","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.02.002"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.10.004"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.76"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.323"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.016"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.5.633"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2008.08.008"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1617"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.599106"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/40187"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.04.012"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.12599","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.12599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:15:45Z","timestamp":1695536145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.12599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,9]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/aos.12599"],"URL":"https:\/\/doi.org\/10.1111\/aos.12599","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,9]]},"assertion":[{"value":"2014-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}